"Erlotinib Hydrochloride" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A quinazoline derivative and ANTINEOPLASTIC AGENT that functions as a PROTEIN KINASE INHIBITOR for EGFR associated tyrosine kinase. It is used in the treatment of NON-SMALL CELL LUNG CANCER.
| Descriptor ID |
D000069347
|
| MeSH Number(s) |
D03.633.100.786.375
|
| Concept/Terms |
CP 358774- CP 358774
- 358774, CP
- CP 358,774
- 358,774, CP
- CP-358,774
- CP358,774
- CP-358774
- CP358774
Erlotinib- Erlotinib
- N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine
|
Below are MeSH descriptors whose meaning is more general than "Erlotinib Hydrochloride".
Below are MeSH descriptors whose meaning is more specific than "Erlotinib Hydrochloride".
This graph shows the total number of publications written about "Erlotinib Hydrochloride" by people in this website by year, and whether "Erlotinib Hydrochloride" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2006 | 0 | 3 | 3 |
| 2007 | 0 | 3 | 3 |
| 2008 | 0 | 7 | 7 |
| 2009 | 0 | 2 | 2 |
| 2010 | 0 | 5 | 5 |
| 2011 | 0 | 3 | 3 |
| 2012 | 0 | 2 | 2 |
| 2013 | 0 | 4 | 4 |
| 2014 | 0 | 2 | 2 |
| 2015 | 3 | 3 | 6 |
| 2016 | 3 | 1 | 4 |
| 2017 | 1 | 4 | 5 |
| 2018 | 0 | 2 | 2 |
| 2019 | 0 | 2 | 2 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 3 | 3 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Erlotinib Hydrochloride" by people in Profiles.
-
BPTF Drives Gastric Cancer Resistance to EGFR Inhibitor by Epigenetically Regulating the C-MYC/PLCG1/Perk Axis. Adv Sci (Weinh). 2023 Dec; 10(34):e2303091.
-
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer. J Clin Oncol. 2023 02 10; 41(5):1105-1115.
-
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial. J Thorac Oncol. 2022 09; 17(9):1086-1097.
-
Profound effects of gastric secretion rate variations on the precipitation of erlotinib in duodenum - An in vitro investigation. Int J Pharm. 2022 May 10; 619:121722.
-
Synthesis, Tumor Specificity, and Photosensitizing Efficacy of Erlotinib-Conjugated Chlorins and Bacteriochlorins: Identification of a Highly Effective Candidate for Photodynamic Therapy of Cancer. J Med Chem. 2021 01 14; 64(1):741-767.
-
Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA. Clin Lung Cancer. 2020 05; 21(3):232-237.
-
Perioperative Gemcitabine?+?Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. Ann Surg Oncol. 2019 Dec; 26(13):4489-4497.
-
Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway. Sci Rep. 2018 12 17; 8(1):17914.
-
The NCI Transcriptional Pharmacodynamics Workbench: A Tool to Examine Dynamic Expression Profiling of Therapeutic Response in the NCI-60 Cell Line Panel. Cancer Res. 2018 12 15; 78(24):6807-6817.
-
Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results. Clin Lung Cancer. 2018 05; 19(3):213-220.e4.